Founded by Drs. Gabriela Chiosis and Larry Norton, Samus Therapeutics is focused on developing innovative treatments for cancer and neurological disorders, including Alzheimer's, Parkinson's, and chronic traumatic encephalopathy. Their lead programs, PU-H71 and PU-AD, are being evaluated in clinical studies for breast cancer, myelofibrosis, and Alzheimer's disease. Additionally, the company is advancing companion diagnostics programs to support their therapeutics.